Valuation: NEOVACS

Market Cap 4.09K 4.71K 3.83K 3.49K 6.57K 449K 6.67K 45.17K 17.6K 225K 17.69K 17.31K 751K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -232K -188K -172K -323K -22.08M -328K -2.22M -865K -11.08M -870K -851K -36.92M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-20.76%
1 week+8.11%
Current month+9.59%
1 month-34.10%
3 months-60.00%
6 months-95.79%
Current year-99.08%
1 week 0.68
Extreme 0.68
1.43
1 month 0.68
Extreme 0.68
1.43
Current year 0.68
Extreme 0.68
267
1 year 0.68
Extreme 0.68
9,879
3 years 0.68
Extreme 0.68
32,000,000
5 years 0.68
Extreme 0.68
351,920,000
10 years 0.68
Extreme 0.68
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 01/10/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 28/05/2003
Director/Board Member - 01/05/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap.
27/02/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-20.76%+8.11%-99.99%-100.00% 185K
-1.60%+1.76%+4.62%+14.41% 49.54B
-0.14%+6.10%+491.53%+584.43% 44.06B
-0.06%+11.16%+23.92%+81.63% 40.85B
-0.87%+5.92%+34.22%+9.95% 40.14B
-4.04%+8.72%+22.60%+48.00% 34.17B
-1.41%+3.81%+32.73%+123.68% 16.9B
+0.35%+4.44% - - 16.78B
-0.43%+1.13%+5.04%+20.83% 14B
+0.84%+21.46%+90.94%+32.60% 13.46B
Average -2.81%+9.92%+67.29%+90.61% 26.99B
Weighted average by Cap. -1.01%+6.51%+106.10%+136.92%

Financials

2023 2024
Net sales 533K 615K 500K 456K 857K 58.6M 870K 5.89M 2.3M 29.4M 2.31M 2.26M 97.99M 434K 500K 407K 371K 697K 47.67M 708K 4.79M 1.87M 23.92M 1.88M 1.84M 79.72M
Net income -8.74M -10.08M -8.2M -7.47M -14.05M -961M -14.27M -96.58M -37.63M -482M -37.83M -37.01M -1.61B -32.91M -37.94M -30.86M -28.11M -52.88M -3.62B -53.71M -364M -142M -1.81B -142M -139M -6.05B
Net Debt -237K -273K -222K -202K -380K -25.98M -386K -2.61M -1.02M -13.04M -1.02M -1M -43.45M -205K -236K -192K -175K -329K -22.53M -335K -2.27M -883K -11.3M -887K -868K -37.68M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
12/08/26 €0.8000 -20.76% 85,188
11/08/26 €1.010 -14.44% 26,133
10/08/26 €1.180 -4.84% 55,132
07/08/26 €1.240 +82.35% 111,566
06/08/26 €0.6800 -5.56% 27,422
  1. Stock Market
  2. Stocks
  3. ALNEV Stock